Lupin and Zentiva in licence and supply deal for Certolizumab Pegol
The partnership will enhance the availability of the affordable biosimilar on a global scale.
Zentiva will manage commercial activities primarily within Europe and CIS markets, excluding the US and Canada.
Meanwhile, Lupin will focus on product development, manufacturing, supply of the medicine within the agreed territories and commercial efforts in the remaining regions, including Canada and the US.
The collaboration involves investment from both companies.
Lupin will receive $10m upon execution of the agreement and could earn up to $50m based on developmental and regulatory milestones.
Profits generated within their respective markets will be shared between Zentiva and Lupin.
The biosimilar is a recombinant humanised antibody Fab' fragment targeting TNFα, conjugated to a 40kDa polyethylene glycol.
Zentiva CEO Steffen Saltofte stated: "Ensuring accessibility to high-quality and affordable healthcare is at Zentiva's core. Our collaboration agreement with Lupin signifies another step forward in our biosimilars and growth strategies.
'Lupin's advanced development and manufacturing capabilities, coupled with our significant market knowledge and presence, mean we can deliver high-quality biosimilar solutions for our customers and their patients, aligning with our purpose of providing health and wellbeing for all generations."
The biosimilar is indicated for conditions including rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis without X-ray evidence (non-radiographic), moderate-to-severe plaque psoriasis and Crohn's disease.
Lupin president of corporate development Fabrice Egros stated: 'Our global development and commercialisation partnership with Zentiva, with its pan-European focus, enables Lupin to commercialise this unique biosimilar in its core markets and through Zentiva in Europe.
'This partnership underscores our dedication to improving the quality of life for individuals living with chronic conditions and ensuring accessibility and affordability of transformative therapies worldwide.'
In March 2025, Lupin entered a licensing and supply agreement with SteinCares to commercialise its biosimilar ranibizumab in Latin American markets excluding Argentina and Mexico.
"Lupin and Zentiva in licence and supply deal for Certolizumab Pegol" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Sibanye Stillwater Limited (SBSW): A Bull Case Theory
We came across a bullish thesis on Sibanye Stillwater Limited on by walter99. In this article, we will summarize the bulls' thesis on SBSW. Sibanye Stillwater Limited's share was trading at $9.24 as of July 25th. SBSW's trailing and forward P/E were 4.67 and 10.94, respectively according to Yahoo Finance. A mine entrance, showcasing the precious metals and minerals that this company produces. Sibanye-Stillwater (SBSW), a major producer of platinum group metals (PGMs)—platinum, palladium, and rhodium—offers a leveraged play on a sector where years of underinvestment and misjudged demand forecasts have created the setup for an extended upcycle. PGMs are essential for automotive catalysts and jewelry, with catalytic converters alone accounting for 43% of platinum and 84% of palladium demand. Market pessimism has been fueled by overestimates of battery electric vehicle (BEV) penetration, but BEV sales growth in the U.S. and Europe flatlined in 2024, suggesting that internal combustion engine and hybrid vehicle demand—and thus PGM demand—will remain resilient. Supply is structurally constrained: South African PGM miners underspent by ~$18 billion over the last decade, 40% of global supply operates at or below cash costs, and production is forecast to decline through 2029. With long lead times for new supply, a persistent deficit projected by the World Platinum Investment Council, and palladium in deficit until at least 2028, any uptick in demand can drive a sharp price response. Recycling, a secondary supply source, remains depressed post-COVID, adding to market tightness. SBSW's profits, crushed by low PGM prices in 2024, have substantial torque to higher prices, as shown in 2020–2021 when the stock hit $20 on elevated metal prices. Today, at $7, platinum's rebound to $1,250 suggests early signs of a cyclical turn. Risks include economic weakness, faster BEV adoption, and rising recycling supply, but with constrained production, a decade of underinvestment, and platinum already rallying, SBSW presents asymmetric upside if PGM prices sustain an upcycle. Previously, we covered a on Sibanye Stillwater Limited (SBSW) by Hugo Navarro in February 2025, highlighting its diversified asset base in PGMs, gold, lithium, and recycling, with growth levers despite weak PGM prices. The stock has appreciated by about 130% as PGM prices rebounded. The thesis still stands, and Walter99 shares a similar view but emphasizes SBSW's leverage to a sustained PGM upcycle. Sibanye Stillwater Limited is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 20 hedge fund portfolios held SBSW at the end of the first quarter which was 18 in the previous quarter. While we acknowledge the potential of SBSW as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18 minutes ago
- Yahoo
Zimmer Biomet Holdings, Inc. (ZBH): A Bull Case Theory
We came across a bullish thesis on Zimmer Biomet Holdings, Inc. on Valueinvesting subreddit by KnowledgePatient7813. In this article, we will summarize the bulls' thesis on ZBH. Zimmer Biomet Holdings, Inc.'s share was trading at $97.55 as of July 25th. ZBH's trailing and forward P/E were 21.68 and 12.27 respectively according to Yahoo Finance. A healthcare professional putting the finishing touches on a patient's knee implant in an operating theater. Zimmer Biomet (ZBH), one of the world's largest makers of orthopedic implants, is viewed as a deeply undervalued turnaround story, trading at just ~12x forward earnings versus competitor Stryker's 32x. The company manufactures artificial knees, hips, shoulders, and surgical tools, operating in a tightly regulated oligopoly with entrenched surgeon loyalty and high barriers to entry. Despite a durable franchise and structural tailwinds from an aging global population. ZBH's stock remains under pressure due to a troubled 2015 Zimmer-Biomet merger that led to recalls, supply chain issues, and market share losses—most notably to Stryker, whose Mako robotic system outperformed ZBH's offerings. Recent cuts to 2025 guidance have reinforced doubts about management's ability to execute a turnaround. Yet, the long-term growth trajectory of joint replacements remains intact, and ZBH has begun addressing operational missteps. The 2022 spin-off of ZimVie simplified the business, and the acquisition of Monogram is aimed at strengthening its ROSA robotics platform to better compete in the high-growth robotic surgery segment. Importantly, the company's entrenched surgeon relationships and FDA regulatory moat create a stickiness that is difficult for competitors to disrupt. With the market pricing ZBH as if its core business is in terminal decline, even moderate operational improvements could drive substantial upside. Investors should watch for margin expansion, stabilization of market share in knees and hips, and tangible traction from ROSA. For value-focused investors, ZBH offers an attractive risk/reward profile: a hated stock with a resilient business model, secular growth tailwinds, and meaningful upside if execution improves. Previously, we covered a bullish thesis on Zimmer Biomet Holdings, Inc. (ZBH) by QuestforYield in March 2025, which highlighted its market leadership, innovation pipeline, and strong free cash flow. The stock has depreciated about 6% since then due to execution concerns. The thesis stands as structural demand drivers remain intact. KnowledgePatient7813 shares a similar view but emphasizes the turnaround potential and undervaluation. Zimmer Biomet Holdings, Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 52 hedge fund portfolios held ZBH at the end of the first quarter which was 53 in the previous quarter. While we acknowledge the potential of ZBH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18 minutes ago
- Yahoo
LyondellBasell Industries N.V. (LYB): A Bull Case Theory
We came across a bullish thesis on LyondellBasell Industries N.V. on DeepValue Capital's Substack. In this article, we will summarize the bulls' thesis on LYB. LyondellBasell Industries N.V.'s share was trading at $62.88 as of July 28th. LYB's trailing and forward P/E were 21.76 and 16.45 respectively according to Yahoo Finance. A factory worker monitoring a conveyor belt of specialty chemicals being produced. LyondellBasell (LYB), one of the world's largest plastics and chemicals producers, operates at the heart of the hydrocarbon-to-plastics value chain, converting oil and gas derivatives into core building blocks like ethylene and propylene, which are polymerized into polyethylene (PE) and polypropylene (PP). These polyolefins account for over 45% of revenue and drive LYB's earnings power, with profitability highly sensitive to spreads between product prices and feedstock costs. The company's U.S. operations benefit from advantaged ethane-based feedstocks, making LYB the lowest-cost large-cap producer globally. Recent performance has been weighed down by trough-level polyethylene pricing, but signs of a cyclical inflection are emerging as PE and PP prices have posted their first consecutive monthly gains in over a year, operating rates are rising, and inventories are normalizing. Macroeconomic tailwinds, including accelerating China stimulus and a bottoming U.S. PMI, support a potential restocking cycle heading into 2026, positioning LYB as a high-leverage beneficiary. Financial quality remains intact with a 10-year median ROIC above 20%, a near-9% dividend yield, a disciplined 70–80% FCF payout policy, and a strong balance sheet. Management has shifted toward disciplined growth with projects like the Flex‑2 propylene unit and MoReTec recycling facility, while keeping capex modest. Shares have fallen over 40% from 2024 highs, pricing in a prolonged downturn. A return to mid-cycle margins and selective growth could expand FCF margins to 12% and lift fair value toward $274, implying ~394% total returns over five years, with LYB offering a compelling combination of scale, structural cost advantage, and early-cycle upside. Previously we covered a bullish thesis on Eastman Chemical Company (EMN) by Necessary-Damage5658 in November 2024, which highlighted its opportunity to gain market share as export controls favor compliant suppliers. The company's stock price has depreciated approximately by 24% since our coverage because the thesis didn't play out amid weaker demand. DeepValue Capital shares a similar but emphasizes LYB's advantaged feedstocks and early-cycle leverage. LyondellBasell Industries N.V. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 38 hedge fund portfolios held LYB at the end of the first quarter which was 46 in the previous quarter. While we acknowledge the potential of LYB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
